Last Updated: May 11, 2026

Details for Patent: 8,871,938


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,871,938 protect, and when does it expire?

Patent 8,871,938 protects BAXDELA and is included in two NDAs.

This patent has forty-nine patent family members in twenty-seven countries.

Summary for Patent: 8,871,938
Title:Process for making quinolone compounds
Abstract:The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.
Inventor(s):Roger Hanselmann, Maxwell M. Reeve, Graham Johnson
Assignee: Melinta Subsidiary Corp
Application Number:US13/937,488
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;

Drugs Protected by US Patent 8,871,938

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes 8,871,938 ⤷  Start Trial Y ⤷  Start Trial
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes 8,871,938 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,871,938

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3214083 ⤷  Start Trial 301091 Netherlands ⤷  Start Trial
European Patent Office 3214083 ⤷  Start Trial 122021000010 Germany ⤷  Start Trial
European Patent Office 3214083 ⤷  Start Trial 132021000000011 Italy ⤷  Start Trial
European Patent Office 3214083 ⤷  Start Trial LUC00196 Luxembourg ⤷  Start Trial
European Patent Office 3214083 ⤷  Start Trial PA2021002 Lithuania ⤷  Start Trial
European Patent Office 3214083 ⤷  Start Trial 2021C/504 Belgium ⤷  Start Trial
European Patent Office 3214083 ⤷  Start Trial CA 2021 00002 Denmark ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.